1.055
0.47%
-0.015
Immunic Inc stock is traded at $1.055, with a volume of 65,494.
It is down -0.47% in the last 24 hours and down -31.29% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$1.07
Open:
$1.08
24h Volume:
65,494
Relative Volume:
0.09
Market Cap:
$93.68M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.3076
EPS:
-3.43
Net Cash Flow:
$-71.16M
1W Performance:
-2.29%
1M Performance:
-31.29%
6M Performance:
-16.14%
1Y Performance:
+0.00%
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
IMUX | 1.0504 | 93.68M | 0 | -93.61M | -71.16M | -3.43 |
VRTX | 446.87 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 741.28 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 590.30 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.22 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.67 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Sep-19-22 | Resumed | H.C. Wainwright | Buy |
Apr-15-21 | Initiated | Aegis Capital | Buy |
Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
Oct-02-20 | Initiated | SVB Leerink | Outperform |
Aug-26-20 | Initiated | Piper Sandler | Overweight |
Aug-07-20 | Resumed | ROTH Capital | Buy |
Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
Jun-05-20 | Initiated | Wedbush | Outperform |
May-11-20 | Initiated | H.C. Wainwright | Buy |
Mar-25-20 | Initiated | ROTH Capital | Buy |
Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Immunic's IMU-856 shows potential in gastrointestinal health trialsICYMI - Proactive Investors UK
Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - MarketBeat
Avidity Partners Management LP's Strategic Acquisition in Immuni - GuruFocus.com
Richard Rudick Spends US$100k On Immunic Stock - Simply Wall St
Insider Buys Additional US$100k In Immunic Stock - Yahoo Finance
Janus Henderson Group PLC's Strategic Reduction in Immunic Inc H - GuruFocus.com
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
RTW INVESTMENTS, LP Acquires Additional Shares in Immunic Inc - GuruFocus.com
Immunic announces publication of IMU-856 data - Yahoo Finance
Director Richard Rudick Acquires 87,300 Shares of Immunic Inc (I - GuruFocus.com
Immunic director Richard Rudick buys $100,368 in stock By Investing.com - Investing.com Australia
Immunic director Richard Rudick buys $100,368 in stock - Investing.com
Immunic announces publication of IMU-856 Phase 1 trial data in peer-reviewed journal - Proactive Investors UK
Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet - Proactive Investors USA
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - PR Newswire
Immunic, Inc. (NASDAQ:IMUX) Q3 2024 Earnings Call Transcript - Insider Monkey
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges By GuruFocus - Investing.com Canada
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic P - GuruFocus.com
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges - Yahoo Finance
Immunic Reports Q3 Earnings and Provides Corporate Update - TipRanks
Immunic, Inc. Advances MS Trials Amid Financial Update - TipRanks
Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Immunic: Q3 Earnings Snapshot - Milford Mirror
Immunic Inc (IMUX) Quarterly 10-Q Report - Quartzy
Immunic Reports Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz
Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones - Proactive Investors USA
Immunic CEO details progress following productive third quarter - Proactive Investors UK
Immunic's Phase 3 MS Trial Advances Despite Wider Q3 Loss; $59.1M Cash Runway | IMUX Stock News - StockTitan
Immunic's Jessica Breu talks BIO-Europe & MS research advancements - Proactive Investors USA
Vanguard Group's Strategic Acquisition of Immunic Inc Shares - GuruFocus.com
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - Quantisnow
Immunic (IMUX) Set to Announce Quarterly Earnings on Thursday - MarketBeat
EQS-News: Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Updateboerse.de - boerse.de
Immunic to Participate in Industry, Scientific and Investor Conferences in November - StockTitan
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.20 - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 29.5% in October - MarketBeat
Reviewing Immunic (NASDAQ:IMUX) & Acasti Pharma (NASDAQ:ACST) - Defense World
We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate - Simply Wall St
Immunic Therapeutics CMO Dr. Andreas Muehler on Positive Interim Analysis for RMS Trials - Proactive Investors Australia
Immunic late-stage program for lead asset to proceed as planned - MSN
Data monitoring committee OKs continuation of phase 3 trial for vidofludimus calcium - Healio
Interim analysis allows Immunic to stick with phase III MS studies - BioWorld Online
Immunic stock slips after trial update (IMUX:NASDAQ) - Seeking Alpha
Immunic Phase 3 MS study advances following positive recommendation from independent committee - Proactive Investors Australia
Immunic Shares Up 12% on Positive MS Drug Analysis - MarketWatch
Immunic's phase 3 ENSURE trials for MS drug proceed as planned - Investing.com
Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - Marketscreener.com
EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosisboerse.de - boerse.de
Immunic Stock Set to Rise with Consistent Buy Ratings from Analysts - Nasdaq
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):